SEARCH

SEARCH BY CITATION

References

  • 1
    Jackson H, Solaymani-Dodaran M, Card TR, Aithal GP, Logan R, West J. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. HEPATOLOGY 2007; 46.
  • 2
    Walley T, Mantgani A. The UK general practice research database. Lancet 1997; 350: 10971099.
  • 3
    Prince MI, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002; 123: 10441051.
  • 4
    Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 12611273.
  • 5
    Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884890.
  • 6
    Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354: 10531060.
  • 7
    Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002; No.1: CD000551.
  • 8
    Lindor KD, Poupon R, Heathcote EJ, Therneau T. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2000; 355: 657658.
  • 9
    Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101: 15291538.
    Direct Link:
  • 10
    Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007; 102: 19.
    Direct Link:
  • 11
    Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C, DeSotel CK, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999; 30: 830835.
  • 12
    Poupon RE, Lindor KD, Pares A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39: 1216.
  • 13
    Poupon RE, Bonnand AM, Chretien Y, Poupon R, and the UDCA-PBC Study Group. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. HEPATOLOGY 1999; 29: 16681671.
  • 14
    Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128: 297303.
  • 15
    Koulentaki M, Moscandrea J, Dimoulios P, Chatzicostas C, Kouroumalis EA. Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment. Dig Dis Sci 2004; 49: 11901195.
  • 16
    Chan CW, Gunsar F, Feudjo M, Rigamonti C, Vlachogiannakos J, Carpenter JR, et al. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Aliment Pharmacol Ther 2005; 21: 217226.
  • 17
    ter Borg PC, Schalm SW, Hansen BE, van Buuren HR. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006; 101: 20442050.
    Direct Link:
  • 18
    Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130: 715720.
  • 19
    Corpechot C, Chretien Y, Chazouilleres O, Poupon R. Biochemical response to UDCA and long-term risk of death or liver transplantation in PBC. J Hepatol 2007; 46( Suppl 1): S49.
  • 20
    Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. HEPATOLOGY 2001; 33: 2227.
  • 21
    James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV. Primary biliary cirrhosis once rare, now common in the United Kingdom? HEPATOLOGY 1999; 30: 390394.
  • 22
    Lee J, Belanger A, Friedman S, Bach N. Transplantation trends among primary biliary cirrhosis patients from 1995 to 2004 [Abstract]. HEPATOLOGY 2006; 44( Suppl): A628.
  • 23
    Agence de la Biomédecine. Rapport Annuel des Activités de Prélèvements et de Greffes Hépatiques en France. 2005. Available at: www.agence-biomedecine.fr.
  • 24
    Lindor KD, for the Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997; 336: 691695.
  • 25
    Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 14641472.